SCN-1 / Scinai Immunotherap - LARVOL DELTA

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb (PRNewswire) - "Scinai Immunotherapeutics Ltd...announced the receipt of minutes of meeting from a recent Scientific Advice ('SA') with the Paul Erlich Institute, Federal Institute for Vaccines and Biomedicines (the 'PEI'), which is considered acceptable guidance for IMPD filing with the European Medicines Agency (EMA) and is also considered the European comparable to a pre-IND meeting with the FDA in the U.S. The Company believes that the minutes of meeting reflect positive regulatory feedback, which can be translated into significant time and cost savings in its IL-17 nanoAb drug development plans."

New P1/2 trial • Preclinical • Psoriasis

Scinai Announces Promising Results in a Psoriatic Human Skin Model (Yahoo Finance) - "Scinai Immunotherapeutics Ltd...is pleased to announce today successful preclinical trial results of its innovative anti–IL–17 VHH antibody ('NanoAb') as a local treatment for the large and underserved population of mild to moderate plaque psoriasis....The statistically significant results demonstrated the potential for Scinai's anti-IL-17 NanoAbs to noticeably improve psoriatic skin lesions as indicated by skin viability and structural integrity. This finding was corroborated by cytokine release analysis, which showed significantly reduced IL-17 release (p<0.001) as compared to the untreated control, similar to the effects of Betamethasone and Cosentyx. These results were further supported by histopathology results demonstrating improved skin structure following a single dose, which appeared more efficient than Betamethasone in reducing inflammation-induced skin and at least as efficient as Cosentyx."

Preclinical • Immunology • Psoriasis

Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results (GlobeNewswire) - "Scinai Immunotherapeutics...announces encouraging results in a preclinical study of Scinai’s anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis....Scinai’s NanoAbs downregulated key molecular markers overexpressed in plaque psoriasis. Stratum corneum regained normal appearance in laboratory 3D skin model. Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-vivo animal study results anticipated in early 2024."

Preclinical • Psoriasis